



# CEO & INVESTOR CONFERENCE

**February 10-11, 2020 • New York, NY**  
New York Marriott Marquis



- [General Overview](#) ▶
- [Advisory Committee](#) ▶
- [Education](#) ▶
- [Partnering](#) ▶
- [Investor Engagement](#) ▶
- [Company Presentations](#) ▶
- [2019 Sponsors](#) ▶
- [Sponsorship Opportunities](#) ▶

**#BIOCE020 • [bio.org/CEO](http://bio.org/CEO)**



**Now in its 22nd year**, the BIO CEO & Investor Conference is one of the largest independent investor conferences focused on established and emerging publicly traded and select private biotech companies.

## Event Attributes and Opportunities

- **Experience the best of biotech** with two-days of productive partnering meetings with institutional investors, industry analysts, and senior biotechnology executives, in one location.
- **Hear Washington's perspective on policy** and other timely developments affecting the industry.
- **Evaluate fresh investment opportunities** including compatible, complementary, and competitive companies.
- **Learn about the hottest clinical developments** and industry catalysts by attending the conference's therapeutic and business-focused panel discussions.
- **Attend fireside chats with senior business leaders** who will share their recent company successes, what keeps the C-suite up at night, and where the industry's leading companies are headed in 2020.
- **Gain access to BIO One-on-One Partnering™** for scouting potential investments and deal partners, optimizing your time at the event.
- **Unique platform for your company** to highlight accomplishments and discuss upcoming milestones. Approximately 170 companies will be chosen based on a selection process evaluating a company's pipeline and R&D activities.
- **Get the pulse** of the current and proposed investment trends in biotechnology.
- **Network with peers, investors, and potential partners** attending the conference and our exclusive receptions.
- **Exclusive sponsorship opportunities** to showcase thought leadership, elevate brand identity and maximize partnering benefits with an elite audience.



**1,200+**  
ATTENDEES



**2,900+**  
PARTNERING MEETINGS



**133**  
COMPANY PRESENTATIONS



**650**  
REGISTERED INVESTORS



**948**  
PARTICIPATING COMPANIES



**33**  
COUNTRIES REPRESENTED

# 2020 Advisory Committee

Each year, BIO assembles a group of industry thought leaders to help us shape the conference program and provide input on key topics and themes that deliver excellence for all attendees.



**Jennifer Hawks Bland**  
Chief Executive Officer  
NewYorkBIO



**Janice Bourque**  
Managing Director,  
Life Sciences  
Hercules Technology  
Growth Capital



**Aoife Brennan, MB, CHB**  
President and CEO  
Synlogic



**Noël Brown**  
Managing Director  
Cantor Fitzgerald



**Vered Caplan**  
CEO and Director  
Orgenesis Inc.



**Jie D'Elia, PhD**  
Executive Director, Business  
Development Transactions  
Bristol-Myers Squibb



**Peter Fong, PhD**  
Senior Principal  
Flagship Pioneering



**Andrew Gitkin**  
Managing Director, Co-Head of  
Healthcare Investment Banking  
Raymond James



**Lan Huang, PhD**  
Co-founder, Chairman and  
Chief Executive Officer  
BeyondSpring



**Anna Kazanchyan, MD**  
Founder and CEO  
Sagmos Therapeutics



**Ciara Kennedy, PhD**  
President and CEO  
Amplex



**Jonathan Leff**  
Partner  
Deerfield Management  
Chairman  
Deerfield Institute



**Lucy Lu, MD**  
President and CEO  
Avenue Therapeutics



**Bibhash Mukhopadhyay, PhD**  
Principal  
New Enterprise  
Associates



**Sara Nayeem, MD**  
Partner  
New Enterprise  
Associates



**Kimberly Nearing**  
Managing Director,  
Head of Life Sciences  
Cedrus Group  
Regional Leader for Bay/Helix's  
NY/NJ/PA Chapters



**Kuldeep Neote, PhD**  
Vice President  
External Innovation  
Eli Lilly and Company



**Susan Peschin, MHS**  
President and Chief  
Executive Officer  
Alliance for Aging  
Research



**Dennis J. Purcell**  
Founder and Senior Advisor  
Aisling Capital



**Yasmeen Rahimi, PhD**  
Managing Director and Senior  
Research Analyst, Co-Head of  
Biotechnology Research  
ROTH Capital Partners



**Stephen Ritoch**  
Chairman and Chief  
Executive Officer  
Blaise Group  
International



**Philip Ross**  
Vice Chairman, Healthcare  
Investment Banking  
J.P. Morgan



**Mahendra Shah, PhD**  
Managing Director  
Vivo Capital



**Jennifer Sheng**  
Managing Director  
Healthcare Equity  
Capital Markets  
Citigroup Global  
Markets



**Marco Taglietti, MD**  
President and CEO  
SCYNEXIS

# Education and Conference Programming

BIO's business and therapeutic panel discussions, plus Fireside Chats with biopharma leaders, provide insights on issues essential to the industry and provide a wealth of information of strategic relevance to help your organization succeed.

## 2019 BIO CEO & INVESTOR CONFERENCE RECAP



### With an Air of Optimism, #BIOCEO19 Concludes

A record number of investors—over 660—registered to learn about the latest biotech trends and to search for opportunities to turn technology into life-saving treatments. More than 130 biotechnology and pharmaceutical companies delivered 13-minute pitches showcasing their pipeline, R&D activities, business objectives and investment goals. Information was also shared through face-to-face meetings scheduled by the BIO One-on-One Partnering system which was in full swing, scheduling almost 3,000 meetings—a record for this 21st annual event.



### Venture Creation is in Vogue

In the biotech industry, it's common for a company to raise billions of dollars and wait more than a dozen years before their investors see a return. That's why capital formation can be an arduous journey in the biotech industry. But the biotech IPO market is coming off of a hot 2018 with more than 50 biotech companies going public on the back of more than \$5.4 billion in funding, marking the second-best year for biotech IPOs in a decade.



### #BIOCEO19: Navigating Payers' Expectations for Value-Based Agreements

Value-based agreements are becoming increasingly important in the biopharmaceutical reimbursement space, particularly as new advanced therapeutic modalities and prospective cures for diseases which previously had no comparable treatments enter the market. Yet the departure from more traditional volume-based reimbursement models poses unique difficulties for biopharmaceutical companies, payers, patients, providers, and investors in planning for a new therapy's rollout and the breadth of patient access to it. This evolving landscape was the subject of a lively and informative discussion on the first day of the 2019 BIO CEO and Investor Conference.



### Policy Outlook—How Could the Trump Administration's Drug Reimbursement Proposals Affect Medical Innovation?

In his State of the Union address, President Trump called on Congress to “do more” to lower drug costs in the United States. Already, the U.S. Department of Health and Human Services (HHS) has proposed piloting an International Pricing Index payment model, tying costs for drugs under Medicare Part B to the lower rates paid in European benchmark countries with socialized medicine. They have moved to lower government costs for drug spending by empowering PBMs and middlemen to dramatically expand the use of utilization management tools like “fail first” that deny patients access to needed medicines. And most recently, HHS proposed changes to the drug rebate system with the goal of eliminating perverse incentives to inflate a drug's list price. Following a year with a record number of new medicines being approved by the FDA, such reforms introduce significant uncertainty for biotech investors. The Policy Outlook—How Could the Trump Administration's Drug Reimbursement Proposals Affect Medical Innovation? session explores the impact these moves have on biomedical investment and innovation.




### Market Outlook—Leveraging Market Corrections for M&A or IPOs

After a multi-year expansion of company formation and in biopharma valuations, 2018 was a year of heightened market volatility. Investors' eagerness to support new modalities enabled more than 50 biotech IPOs, but with much less mature clinical development progress than traditionally demonstrated. More than half those companies are trading below their IPO prices, however, complicating conditions for the next new offering. As interest rate worries, international trade disputes, and regulatory reimbursement uncertainty have increased, biopharma stock indexes have seen significant corrections. With historically high valuations experiencing sudden dips, M&A deal-making seems to have reignited with notable, multi-billion dollar deals in recent weeks. The Market Outlook—Leveraging Market Corrections for M&A or IPOs session brought together market experts to discuss what forces continue to shape performance within the sector and what opportunities the market correction can reveal for investors and companies seeking resources to deliver the next wave of innovative therapies for patients.

## Partnering


BIO One-on-One Partnering is the most efficient way to do business in the biotech and pharma industry without traveling all over the world. Our system makes it easy to search for and identify potential partners and request meetings with prospective biotech investors and senior business development executives.



### Representative Program Speakers

- **Aoife Brennan, MD, CHB**, Chief Executive Officer and Chief Medical Officer, Synlogix, Inc.
- **Brian K. Kaspar, PhD**, Chief Scientific Officer, AveXis
- **Ciara Kennedy, PhD**, President and Chief Executive Officer, Amplyx
- **Geoff Meyerson**, Managing Partner and Co-Founder, Locust Walk
- **Ron Philip**, Chief Commercial Officer, Spark Therapeutics
- **Nancy Thornberry**, Chief Executive Officer, Kallyope
- **Philip Ross**, Vice Chairman, J.P. Morgan
- **William Slattery**, Partner, Deerfield
- **Erica Whittaker, PhD**, Head of UCB Ventures, UCB Pharma
- **Lynn O'Connor Vos**, President and CEO, Muscular Dystrophy Association

[Full Program ▶](#)



### Representative Companies


- Ascleptis Pharma
- Alnylam Pharmaceuticals
- Celgene
- Daré Bioscience
- MaxCyte
- Mitsubishi Tanabe Pharma
- Neurotrope
- Redhill Biopharma
- Sanofi
- Vyriad

[Full Company List ▶](#)



# Investor Engagement

With an industry that is rapidly and dynamically shifting, the BIO CEO & Investor Conference is a perfect balance of educational content that help investors stay attuned to issues that are relevant to peers and current/future clients while also providing an exclusive venue to source new frontiers in discovery and ensure high-quality interactions between corporate and investor colleagues.



## Representative Investors

- Aisling Capital
- Andreessen Horowitz
- Arch Venture Partners
- GE Ventures
- Hercules Capital
- MPM Capital
- OrbiMed Advisors
- Sofinnova Ventures
- The Carlyle Group
- Vivo Capital

## 2019 Participating Investors

- |  |  |                               |  |   |   |
|--|--|-------------------------------|--|---|---|
| 3E Bioventures                                       | Bridge Bank                                | Genoa Ventures                | Lilly Asia Ventures                            | Olive Tree Capital                        | Special Situations Funds                              |
| AbbVie   | Brook Capital Group                        | GHS Investments               | Lincoln Park Capital                           | Oncolytics Biotech                        | Square 1 Bank   |
| Accelerator Life Science Partners                    | Brookline Capital Markets                  | Global Corporate Finance      | Livingston                                     | Oppenheimer & Co                          | StarLink Capital                                      |
| Aceras BioMedical                                    | Brothers & Partners Europe                 | Global Health Investment Fund | Locust Walk                                    | Opti Capital Management                   | SternAegis Ventures                                   |
| Acuris Partners                                      | Bryan, Garnier & Co                        | Global Source Ventures        | Longitude Capital                              | Orchard View Capital Advisors LP          | SunTrust Robinson Humphrey                            |
| Adjuvant Capital                                     | BTIG                                       | Golden Seeds                  | Lord Abbett                                    | Orion Consultoria Financeira              | Surveyor Capital                                      |
| AE Capital   | Capgenic Advisors                          | Goldwater Asset Management    | LSWorks  | Otsuka Pharmaceutical Co.                 | SV Investment   |
| Aegis Capital Corp.                                  | Cato BioVentures                           | Good Health Capital           | Lumira Capital                                 | Oxford Finance                            | Symphonia Partners                                    |
| Affinity Asset Advisors                              | Caxton Alternative Management LP           | Gorlin Companies              | Madison Square Capital                         | Pappas Capital                            | Taglich Private Equity                                |
| Agent Capital  | CBI Capital                                | Gradus/RSJ Private Equity     | Magid Family Office                            | Park Ave. Capital Management              | Talhim Investments                                    |
| AIG Global Investment Corporation                    | C-Bridge Capital                           | GreenSky Capital              | Maxim Group                                    | International                             | Tanaka Capital Management                             |
| Aisling Capital                                      | CEC Capital Group                          | Grey Sky Venture Partners     | Maxim Merchant Capital                         | Paulson Investment Company                | Tap Advisors  |
| Aleph Capital  | Cedrus Investments                         | Griffin Securities            | MayTech Global Investments                     | Peak One Investments                      | Terra Magnum Capital Partners                         |
| Alignment Ventures                                   | Chardan Capital Markets                    | Guggenheim                    | MAZ Capital Advisors                           | Peter B. Cannell & Co.                    | The Anson Group                                       |
| Alpha BioLabs  | Charlestown Capital                        | H.C. Wainwright & Company     | Medexplore Ventures                            | Petrichor Healthcare Capital Management   | The Astrologers Fund                                  |
| Alpha Blue Ocean Advisors                            | Chronon Capital                            | H.I.G. BioHealth Partners     | Mediquventures                                 | The Carlyle Group                         | The Leukemia & Lymphoma Society                       |
| Alpha Holdings                                       | CJ Seligman & Co.                          | H.I.G. Capital                | MEDX Ventures Group                            | The Mark Foundation for Cancer Research   | The Lind Partners                                     |
| Andreessen Horowitz                                  | Cowen and Company                          | Harbin Pharmaceutical Group   | Merlin Nexus                                   | Pfizer                                    | The Mark Foundation for Cancer Research               |
| Aperture Venture Partners                            | Cowen Healthcare Investments               | Harborview Capital            | Mid Atlantic Bio Angels                        | Pharmakon Advisors                        | The Mark Foundation for Cancer Research               |
| Aracle Capital                                       | Cowin Capital                              | Hartford Financial Mgmt       | Militia Hill Ventures                          | Pipeline Angels                           | TransPacific Venture Capital Partners                 |
| Arch Venture Partners                                | Crown Point Group                          | Hayfin Capital Management     | Mithril Capital Management                     | Pipeline Capital                          | Trevie Capital  |
| Aristar Capital                                      | CRV  | HCM                           | Mitsui & Co. Global Investment                 | Piper Jaffray Ventures                    | Tryphon Capital Advisors                              |
| Arix Bioscience                                      | CS McKee                                   | HealthCare Royalty Partners   | Mizuho Bank                                    | Prevail Partners                          | Turret Capital Management                             |
| Ashford Capital Management                           | CSC Leasing                                | Helicase Venture              | Mizuho Securities                              | Princeton Biopharma                       | Unum Capital  |
| Aspire Capital                                       | CTI Life Sciences                          | Helix Management              | Momentum Biotech                               | Promethean Capital Group                  | Upstream Partners                                     |
| Asset Management Ventures                            | CTIQ Pharmaceutical Group                  | Hemi Ventures                 | Montrose Capital Partners                      | Quantum Capital Partners                  | V2m Life Sciences Fund                                |
| Astute Capital                                       | Dabar Investment Associates                | Hercules Capital              | Mossrock Capital                               | Quan Capital                              | Vector Resource Funds                                 |
| ATEL Ventures Inc                                    | Dec Family Ventures                        | HI Investors Capital          | MP Healthcare Venture Management               | Radius Financial                          | Versant Ventures                                      |
| Athena Bio Ventures                                  | Deca Ventures                              | Hood River Capital Management | MPM Capital                                    | Red Hook Asset Management                 | Vida Ventures   |
| Atheneo Ventures                                     | Delos Capital Partners/Delos Life Sciences | Hudson East Capital           | MSAB Capital                                   | Remsen Investors LP                       | Viva Biotech Holdings                                 |
| ATW  | Deltec Bank                                | Humanwell Healthcare Group    | MSQ Ventures                                   | Repertoire Asset Management               | Vivo Capital  |
| Aurora Capital, LLC                                  | DHVC                                       | Iaso Ventures                 | Muirfield Capital                              | RHK Capital                               | W Global Capital Ltd/International Capital Management |
| B. Riley FBR   | Diamondback Capital Management             | IDG Capital Partners          | Murdock Capital Partners Corporation           | RoIn                                      | Wallachbeth Capital                                   |
| Band of Angels                                       | Douglas C. Lane & Associates               | Illumina Ventures             | MV Corp Services                               | ROTH Capital Partners                     | Watermill Asset Management                            |
| Bank of America Merrill Lynch Global Research        | Dynamk Capital                             | Image Analysis Group          | MVP Capital Partners                           | Royalty Pharma Management                 | WBB Asset Management                                  |
| BE Capital   | E Squared Capital Management, LLC          | INKEF Capital                 | NauVista Capital Management                    | Santen Pharmaceutical Co.                 | WBB Securities, LLC                                   |
| Beacon Capital                                       | Easton Capital                             | InMed Pharmaceuticals         | NCL Technology Ventures                        | Sarasota Investments                      | Wells Fargo   |
| Berenberg Capital Markets                            | Efrat Investments                          | Integrium                     | Needham & Company                              | Satter Medical Technology Partnership     | WestPark Capital                                      |
| BHP Capital  | Entech Bio                                 | Jafco Co.                     | Neurotrope                                     | SBP Management                            | Wexford Capital                                       |
| BIMA Capital   | Esousa Holdings                            | JBS Healthcare Ventures       | New Harbor Venture Partners                    | SC Fundamental                            | Whitwell Partners                                     |
| Biadvantage-The Biotech Greenhouse Corp of Southeast | Everpine Capital                           | Jefferies                     | New Science Ventures                           | Scopus Ventures                           | Wolf Capital Management                               |
| Bioledeans   | EVOLUTION Life Science Partners            | Jina Ventures                 | New York City Economic Development Corporation | Second Line Capital Mgmt                  | Wolpert Associates                                    |
| BiInnovation Capital                                 | Fannin Innovation Studio                   | Johnston Associates           | NGN Capital                                    | Seroba Life Sciences                      | Xeraya Capital Life Venture                           |
| Biondo Investment Advisors                           | FO Capital Management                      | JP Morgan                     | NJAngels                                       | Serrado Capital                           | YA Global   |
| BioSense Global                                      | Fiera Capital                              | Kalka Fund LP                 | Noble Equity Fund                              | Shanghai Fosun Pharmaceutical (Group) Co. | Yale University                                       |
| Biotech Alliances International                      | First Island Capital                       | Katalyst Securities           | Nordcon Capital                                | Shaw Strategic Capital                    | YILGA Management Services                             |
| Bioventure Partners                                  | Foreste Capital Management                 | Knoll Capital Management      | Northern Light Venture Capital                 | Shenzhen Salubris Pharmaceuticals Co.Ltd  | Yonjin Capital  |
| Black Diamond Advisors                               | Fortress Biotech                           | L1 Capital                    | Novato Ventures                                | Simrx Advisors                            | Young America Capital                                 |
| BMO Capital Markets (U.S.)                           | Fortunatus Capital                         | L2 Capital                    | NSIP   | Sio Capital Management                    | Yuhan USA   |
| BOHE Angel Fund                                      | Fosun Pharma                               | Ladenburg Thalmann            | NYS Medtech/Perselson                          | Sofinnova Ventures                        | Zacks SCR   |
| Bojan Capital  | Foxhill Asset Management                   | Laidlaw & Company             | NYS Innovation VC Fund                         | Sorrento Therapeutics                     | Zenity Holdings New York                              |
| Borex Capital  | GCF Family Office                          | Landmark Angels               | OCV  |   |   |
|  | GE Ventures                                | LifeScience EquityPartners    |  |   |   |
|  |  | LifeTech Capital              |  |   |   |

# Company Presentations

Opportunity for biotechnology and pharmaceutical companies to do 13-minute pitches showcasing their pipeline, R&D activities, business objectives and investment goals. Presenting companies are hand-selected for the event and consist of mid-to large-cap established public companies, and select private companies, from around the globe.

## 2019 PRESENTING COMPANIES

### Cardiovascular

Espero BioPharma  
InCarda Therapeutics  
Resverlogix Corp.  
Verseon

### CNS/Neurological

Anavex Life Sciences  
Bioasis Technologies Inc.  
BioXcel Therapeutics  
Cox Biosciences LLC  
E-Scape Bio  
EIP Pharma, Inc.  
Knopp Biosciences  
NeuroRx  
Newron Pharmaceuticals SpA  
NoNO Inc.  
ORYZON  
Otsuka Pharmaceutical  
PAION AG  
Serina Therapeutics, Inc.  
Tonix Pharmaceuticals Holding Corp.  
Trevena, Inc  
Vallon Pharmaceuticals  
VistaGen Therapeutics, Inc.  
Zynerba Pharmaceuticals

### Dermatology

Azitra Inc.

### Diagnostics

BioMarker Strategies, LLC  
Genes2me LLP  
Interpace Diagnostics  
OncoCyte

### Digital Health

Congenica Ltd  
Lumme Inc

### Gastrointestinal

Cancer Prevention Pharmaceuticals  
Landos Biopharma  
Mirum Pharmaceuticals  
Synthetic Biologics, Inc.

### Gene/Cell Therapy

American Gene Technologies  
Brainstorm Cell Therapeutics  
Cesca Therapeutics Inc.  
Eloxx Pharmaceuticals  
Fibrocell Science, Inc.  
MeiraGTX

### Immunology

Abcuro, Inc.  
aTyr Pharma, Inc.  
INmune Bio  
Immunic AG  
ImmuneSYS, Inc.

### Infectious Diseases

Amplix Pharmaceuticals Inc.  
CytoDyn Inc.  
Summit Therapeutics  
VenatoRx Pharmaceuticals

### Medical Devices

Arch Therapeutics, Inc.  
CytoSorbents  
Femeda Ltd

### Metabolic Diseases

CohBar, Inc.  
SERAXIS INC.

### Multiple Therapeutics

Alnylam Pharmaceuticals  
LifeEDIT  
Lyndra Inc  
Q BioMed Inc  
Sirnaomics, Inc

### Non-Profit/Patient Advocacy Group

National Health Council Patient-Centered Health  
Care Accelerator

### Oncology

Actinium Pharmaceuticals, Inc.  
AIVITA Biomedical  
AUM Biosciences  
CASI Pharmaceuticals, Inc.  
CEL-SCI Corporation  
Collectar Biosciences  
Cue Biopharma  
Curis, Inc  
Cyclacel Pharmaceuticals, Inc.  
Exicure  
Greenwich LifeSciences  
Heat Biologics, Inc.  
Immunicum AB  
ImmunoMet Therapeutics  
Immunomic Therapeutics, Inc.  
IMV Inc.  
Infinity Pharmaceuticals  
Kleo Pharmaceuticals  
MaxCyte, Inc.  
Oncolytics Biotech Inc.  
Onconova Therapeutics, Inc.  
OxSonic Limited  
Propanc Biopharma Inc.

Salarius Pharmaceuticals  
Sapience Therapeutics  
SATOR Therapeutics LLC  
SELLAS Life Sciences Group, Inc.  
Senti Biosciences  
Sutro Biopharma, Inc.  
Tarveda Therapeutics, Inc  
Trovagene Oncology  
Vyriad, Inc.  
Zenith Epigenetics

### Ophthalmology

EyeGate Pharmaceuticals, Inc.  
Nemus Biosciences  
Nicox SA  
OcuMedic, Inc.  
Oxurion NV  
Oyster Point Pharma, Inc.

### Orphan/Rare Diseases

Arcturus Therapeutics  
Catalyst Biosciences  
Catalyst Pharmaceuticals, Inc.  
Children's Tumor Foundation  
Fulcrum Therapeutics  
Lung Therapeutics

### Other

Rockwell Medical, Inc  
Select Greater Philadelphia

### Platform for Therapeutics

Anima Biotech Inc.  
Aquestive Therapeutics  
Oramed Pharmaceuticals  
Second Genome, Inc

### Regenerative Medicine

Aspect Biosystems  
Caladrius Biosciences, Inc  
Carmell Therapeutics  
SpinalCyte, LLC

### Reproductive/Sexual Health

Daré Bioscience  
Urigen Pharmaceuticals, Inc.

### Respiratory

ProterixBio, Inc  
Tenax Therapeutics, Inc.  
Verona Pharma

### Tools/Drug Development Support Tech

AbMax Biotechnology CO., LTD  
Precision NanoSystems

## 2019 BUZZ of BIO Winners

PUBLIC THERAPEUTIC BIOTECH

**bioasis**

PRIVATE THERAPEUTIC BIOTECH

**LANDOS**  
BIOPHARMA

DIAGNOSTICS AND BEYOND

**Lumme**  
Detect. Predict. Prevent.



# 2019 Sponsors

## DOUBLE HELIX SPONSORS



Bristol-Myers Squibb



## SUPPORTING BANK SPONSORS



## CONFERENCE SPONSORS







## LOCAL CO-HOST





# 2020 Sponsorship Opportunities

	Number of Registrations	Recognition on Conference Website, Materials and Signage	Advertisement in Conference Program	Access to BIO One-on-One Partnering	Partnering Suite and Priority Scheduling of Meetings	Guaranteed Speaking Opportunity
<b>Showcase Thought Leadership</b>						
 Program Sponsor	3	✓	✓	✓	✓	✓
Company Presentations Sponsor	2	✓	✓	✓		
<b>Access Your Target Audience</b>						
Welcome Reception Sponsor	2	✓	✓	✓		
 Hospitality Sponsor	2	✓	✓	✓		
Closing Reception Sponsor	2	✓	✓	✓		
BIO Showcase Tabletop Sponsor	2	✓	✓	✓		
<b>Maximize Partnering &amp; Deal Making</b>						
 BIO One-on-One Partnering System Sponsor	3	✓	✓	✓	✓	
Partnering Suite Package	2	✓	✓	✓	✓	
Partnering Lounge Sponsor	2	✓	✓	✓	✓	
<b>Boost Brand Visibility</b>						
Conference Bag Sponsor	2	✓	✓	✓		
Lanyard Sponsor	2	✓	✓	✓		
Conference Program Sponsor	2	✓	✓	✓		
WiFi Sponsor	2	✓	✓	✓		
 Buzz of BIO Contest Sponsor	2	✓	✓	✓		
Social Media Sponsor	2	✓	✓	✓		
Luggage and Coat Check Sponsor	2	✓	✓	✓		
Charging Station Sponsor	1	✓	✓			
Hotel Key Card Sponsor	1	✓	✓			
Good Day BIO Sponsor	2	✓	✓			
<b>Print &amp; Digital Advertising</b>						
Daily Buzz Email Sponsor	1	✓	✓			
 Conference Program Advertisement	0		✓			
Digital Advertising	0					
High Visibility Signage	0					

► Our Sales & Sponsorship team is always ready to support your event engagement. Please feel free to reach out to the team at [+1.202.312.9264](tel:+12023129264) or [sponsor@bio.org](mailto:sponsor@bio.org).